TB-500

The TB-500 evidence base cited here is 10 sources — 2 clinical, 6 preclinical, 2 review. Its strongest evidence is human — 2 clinical studies, most recently 2015 ("Thymosin Beta-4 Ophthalmic Solution for Dry Eye — Phase II RCT"). Regulatory status: Not FDA-approved.

• TB-500 is a synthetic version of the active region (the Ac-LKKTETQ sequence) of thymosin beta-4, a natural 43-amino-acid protein the body uses for tissue repair, cell migration, and wound healing.
• Its core mechanism is binding G-actin to reorganize the cell's cytoskeleton — that's what lets cells migrate to injury sites — alongside anti-inflammatory effects, new blood-vessel growth, and stem/progenitor-cell mobilization.
• Most human-relevant data is on the parent protein (thymosin beta-4), not the TB-500 fragment, and is concentrated in wound-healing and cardiac/eye trials. Musculoskeletal use in humans is essentially anecdotal.

TB-500 is a lab-made peptide fragment built from the active part of thymosin beta-4 (Tβ4), a protein found throughout the body — thymus, spleen, lungs, brain, heart — that plays a central role in tissue repair, cellular regeneration, and wound healing. It's studied mostly for soft-tissue and tendon recovery and is popular with athletes and biohackers chasing faster injury repair.

The honest framing up front: the encouraging results are largely preclinical (animal models) or come from trials on the full thymosin beta-4 protein rather than the TB-500 fragment itself. There are no large human trials for the musculoskeletal uses people actually buy it for. It's not FDA-approved and it's banned in sport. Everything below is research context, not medical advice.

TB-500 corresponds to the active region of thymosin beta-4 — specifically the short Ac-LKKTETQ sequence responsible for much of the parent protein's actin-binding and repair activity. Thymosin beta-4 was originally isolated from the thymus by Goldstein and White, then later found at high concentration in tissues all over the body.

Because it's a fragment of a naturally occurring repair protein rather than a novel drug, research interest has centered on whether it can reproduce Tβ4's documented effects — cell migration, reduced inflammation, angiogenesis, and accelerated soft-tissue recovery — in a smaller, easier-to-manufacture molecule. Whether the fragment performs identically to the full protein in humans is still an open question.

No dosing has been established through human clinical trials. The figures below come from anecdotal use and extrapolation from research settings, included for research context only.

• Loading: ~1.0–1.5 mg twice weekly (≈2–3 mg/week total) for roughly 4–6 weeks
• Maintenance: drop to ~1–2 mg once weekly after the loading phase
• Typical run length: 4–6 weeks active, often 2–4 weeks off before resuming
• Chronic injuries may be cycled over longer/adjusted periods in reports

Because TB-500 distributes systemically, injecting 'near the injury' isn't clearly necessary — though many users do it anyway for perceived local effect.

TB-500 is reconstituted and injected; oral dosing isn't viable because the peptide wouldn't survive digestion. None of these routes have been formally studied for the fragment.

• Subcutaneous (most common) — into fatty tissue of the abdomen, thigh, or upper arm; slow absorption suits a systemic signaling peptide.
• Intramuscular — sometimes used to target a specific muscle injury.
• Rotate injection sites and use sterile technique (alcohol-clean the site, new needle each time) to avoid local irritation.
• Start lower and titrate up to assess tolerance.

• Weeks 1–2: some report reduced inflammation and mild comfort improvements at injury sites.
• Weeks 2–4: reported gains in mobility, recovery speed, and energy.
• Weeks 4–8: where most reported tissue-repair, flexibility, and functional-recovery milestones cluster.
• Months 2–6: benefits reportedly continue building with consistent use, especially for chronic injuries.

These timelines are user reports, not trial endpoints — individual response varies and none of this is verified in controlled human studies of the fragment.

Most rigorous evidence is for the parent protein, thymosin beta-4, rather than the TB-500 fragment specifically. The standout caveat: large-scale human trials for musculoskeletal recovery — the main reason people use it — don't exist.

Bottom line: thymosin beta-4 has a real, if early, clinical footprint in wound healing; the TB-500 fragment's musculoskeletal reputation rests largely on extrapolation and anecdote.

Most commonly paired with BPC-157 in the so-called 'Wolverine stack.' Research context, not protocol advice — the rationale is complementary mechanisms: BPC-157 for localized healing and collagen synthesis, TB-500 for systemic cell migration and angiogenesis.

• Wolverine stack: TB-500 2.0–2.5 mg twice weekly (loading) then weekly; BPC-157 250–500 mcg daily.
• GH secretagogues (Ipamorelin, CJC-1295) — systemic anabolic/regenerative support.
• GHK-Cu — collagen production and broader tissue support.

• Comes as lyophilized powder; bring vial to room temperature, add bacteriostatic water slowly down the vial wall, and swirl gently — don't shake.
• Common ratio: 5 mg + 5 mL BAC water = 1 mg/mL (1 mg per 1 mL / 100 units on an insulin syringe).
• Lyophilized: refrigerate or keep cool/dry (tolerates room temp briefly). Reconstituted: 2–8°C, stable ~3–4 weeks; never freeze; protect from light and heat.

TB-500 is generally described as well-tolerated, and thymosin beta-4 showed a favorable safety profile in clinical trials with minimal adverse effects. Human safety data for the fragment specifically is limited, so the reports below are anecdotal or plausible-but-undemonstrated.

Long-term effects of extended use aren't well understood, and research-grade product is unregulated — purity and contamination are real considerations.

• Not FDA-approved for any human medical use.
• The FDA classifies TB-500 (thymosin beta-4) as a substance with safety concerns, barring it from 503A/503B compounding — recent FDA actions have tightened access through pharmacies.
• Can't legally be sold as a drug, food, or supplement for human consumption; sold only as a 'research chemical' not for human use.
• Not DEA-scheduled, so possession itself isn't illegal.

Research-grade TB-500 is for laboratory research only — not intended for human consumption, and from an unregulated market where purity isn't guaranteed.

TB-500 and thymosin beta-4 are prohibited under the WADA Prohibited List, falling under S2.3 (growth factors, related substances, and mimetics), and were explicitly named as examples in the 2018 list update. The ban applies both in- and out-of-competition, so tested athletes can't use it at any point in their competitive careers — positive tests carry bans and disqualification across any sport body following WADA rules.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.